Replies to post #111505 on Avid Bioservices Inc (CDMO)

[senrex]

I feel that because the MOA of Bavituximab is to stimulate the immune system, and that this does not necessarily occur overnight, that fast growing cancers may not be the best candidates for us in trials designed to "Knock our Socks off!"

I think the immuno-effecting aspect of this drug may well be the characteristic we all remember in the end.

[biopharm]

There is something to think about in the reality that big drug companies have the clout to get the most treatable patients for their trials, and the rest are left to companies like Peregrine. So in a
way I am not as disappointed as some here, because I feel that we showed a positive outcome on a very difficult treatment population.

Agreed and everyone needs to remember, stage IV pancreatic cancer is considered one of the absolute worst to be diagnosed with and Bavi did double the response rate. The key is going to be comparing the ones that lived beyond 12 months.... to those that passed more quickly. Its this comparison that will tell much more and unfortunately we don't have all the detailed trial data.

Avastin is the largest $$$ sales oncology drug.... and Peregrine's Bavi will meet and best Avastin (imho) when all is said and done.

We've come a long way from hearing Bavi doesn't work.. its a placebo... etc..etc...

This trial was further proof that Bavi works.... its like we're just floating around in the ocean in a big mass of fog and when it all clears.... Bavi will indeed be moving ahead for multiple FDA approvals.

GLTA!

[freethemice]

Don't get me wrong. I still think Bavi will work well with other indications, just not pancreatic cancer.
This is not the end of it. To me it seems that the understanding of pancreatic cancer is lacking.
Bavi's MOA may be thwarted in some way in this cancer, or the patients were just too far gone
to give bavi a chance to help them. It will take more research. In the meantime Peregrine will have
to move on to more promising cancers, like breast cancer.